Study design (if review, criteria of inclusion for studies)
Randomised parallel group trial
Mean age 10.7 years, range 6 years to 15 years n = 56 CF Females = 30 CF Males = 26
Mistabron 20% 3 ml BD for 8 weeks versus HS 7% 3 ml BD for 8 weeks. No reported pre-treatment
PEFR, FVC, V max 50% VC, RV/TLC
No significant changes were found in five patients with no measurable sputum production. The inhalations were given after physiotherapy and were well tolerated. There were no significant side effects.
The results suggest that Mistabron has a beneficial therapeutic effect unrelated to its high osmolality, and the intermittent inhalation of Mistabron may have a role in the treatment of selected patients with cystic fibrosis.